Valuation
- Market cap
- —
- Revenue TTM
- $0
- Net income TTM
- $0
- P/E (trailing)
- —
- P/E (forward)
- —
- Profit margin
- 0.00%
- Debt to equity
- —
Trading
- Volume
- 10,800
- Avg volume
- 6,592
- Day's range
- $0.31 – $0.32
- Shares out
- —
- Stochastic %K
- 11%
- Beta
- —
- Analysts
- —
- Price target
- —
Company profile
Biomark Diagnostics Inc. develops early-stage cancer diagnostic technology platform to detect and treat cancer. The company invests in and develops a liquid biopsy metabolic panel assay for the early-stage diagnosis of lung cancer and glioblastoma (GBM) breast cancer. It is also developing liquid biopsy tests for various cancer types, including glioblastoma, gastrointestinal, prostate, head, neck cancers. The company...
Show more
Biomark Diagnostics Inc. develops early-stage cancer diagnostic technology platform to detect and treat cancer. The company invests in and develops a liquid biopsy metabolic panel assay for the early-stage diagnosis of lung cancer and glioblastoma (GBM) breast cancer. It is also developing liquid biopsy tests for various cancer types, including glioblastoma, gastrointestinal, prostate, head, neck cancers. The company was incorporated in 2014 and is headquartered in Richmond, Canada.
- Industry
- Diagnostics & Research
- Sector
- Healthcare
- Phone
- 604-370-0779
- Website
- https://www.biomarkdiagnostics.com
- Address
- 3851 Shell Road, Suite 130, Richmond, Canada
Latest news
No headlines yet.
